VivoSim Labs, Inc. - Common Stock (NQ:VIVS)
0.2608
-0.0307
(-10.53%)
Official Closing Price
Updated: 4:15 PM EST, Nov 20, 2026
Add to My Watchlist
All News about VivoSim Labs, Inc. - Common Stock
Via Chartmill
US Top Movers for Nov. 19, 2026: Gainers and Losers ↗
November 19, 2026
Via Chartmill
Most Active Stocks on Nov. 19: VIVS, CHSN and NVDA Top Volume ↗
November 19, 2026
Via Chartmill
Via Chartmill
Gap Stocks on November 19, 2026: Vivid Seats and NewGenIvf Lead Movers ↗
November 19, 2026
Via Chartmill
Premarket Small-Cap Movers: Nov. 19, 2026 Gainers and Losers ↗
November 19, 2026
Via Chartmill
VivoSim Labs and Chemveda Move Human-Tissue Testing Earlier in AI Drug Development
November 13, 2026
Via AB Newswire
Topics
Artificial Intelligence
Post-Midterm Market Sectors and Companies Inside to Watch
November 05, 2026
Via AB Newswire
3 Stocks Under $1: INO, VIVS, FNUC in Focus for November
November 03, 2026
Via AB Newswire
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via AB Newswire
Topics
Artificial Intelligence
Via AB Newswire
2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus
October 01, 2026
Via AB Newswire
2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!
September 28, 2026
Via AB Newswire
Topics
Artificial Intelligence
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed Drugs
September 28, 2026
Via AB Newswire
Via AB Newswire
Topics
Government
Via AB Newswire
Topics
Animal Testing
High-Impact Stocks DRK, VIVS, AEMD, GMG in the News
September 17, 2026
Via AB Newswire
From VivoSim Labs, Inc.
Via GlobeNewswire
Catch the Danger, Spare the Cure: Why VivoSim’s (NASDAQ: VIVS) 90%/95% Toxicity Results Matter
September 14, 2026
Via AB Newswire
Topics
Artificial Intelligence
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
September 10, 2026
Via AB Newswire
VivoSim Labs (NASDAQ: VIVS) Opens New Pharma Opportunity
September 02, 2026
Via AB Newswire